NCEL NASDAQ
NewcelX Ltd.
1W: -3.4%
1M: -14.9%
3M: -27.1%
YTD: +36.4%
$2.85
-0.06 (-2.06%)
Weekly Expected Move ±7.3%
$2
$3
$3
$3
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider+$0.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3M
52W Range1.83-21.3
Volume2,957
Avg Volume44,053
Beta0.93
Dividend—
Analyst Ratings
Company Info
CEORonen Twito
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2025-10-24
Websitenewcelx.net
Hohstrasse 1
Kloten, ZH 8302
CH
Kloten, ZH 8302
CH
972 73 797 1600
About NewcelX Ltd.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Latest News
NewcelX GAAP EPS of -$0.96
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission
NLS Pharmaceutics GAAP EPS of -$2.16
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Samuel Olivier | P-Purchase | 114,545 | $3.02 | 2026-04-27 |
| Samuel Olivier | P-Purchase | 81,818 | $2.75 | 2026-04-27 |
| Revel Michel | P-Purchase | 54,545 | $2.75 | 2026-04-27 |
| Revel Michel | P-Purchase | 76,363 | $3.02 | 2026-04-27 |
| Galili Tamar | 9,117 | $7.62 | 2026-03-18 |